Men with Mutations
BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients.
Kote-Jarai Z, Leongamornlert D, Saunders E, Tymrakiewicz M, Castro E, Mahmud N, Guy M, Edwards S, O'Brien L, Sawyer E, Hall A, Wilkinson R, Dadaev T, Goh C, Easton D; UKGPCS Collaborators, Goldgar D, Eeles R. Br J Cancer, 105(8): p. 1230-1234. October, 2011.
Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study
Mitra AV, Bancroft EK, Barbachano Y, Page EC, Foster CS, Jameson C, Mitchell G, Lindeman GJ, Stapleton A, Suthers G, Evans DG, Cruger D, Blanco I, Mercer C, Kirk J, Maehle L, Hodgson S, Walker L, Izatt L, Douglas F, Tucker K, Dorkins H, Clowes V, Male A, Donaldson A, Brewer C, Doherty R, Bulman B, Osther PJ, Salinas M, Eccles D, Axcrona K, Jobson I, Newcombe B, Cybulski C, Rubinstein WS, Buys S, Townshend S, Friedman E, Domchek S, Ramon Y Cajal T, Spigelman A, Teo SH, Nicolai N, Aaronson N, Ardern-Jones A, Bangma C, Dearnaley D, Eyfjord J, Falconer A, Grönberg H, Hamdy F, Johannsson O, Khoo V, Kote-Jarai Z, Lilja H, Lubinski J, Melia J, Moynihan C, Peock S, Rennert G, Schröder F, Sibley P, Suri M, Wilson P, Bignon YJ, Strom S, Tischkowitz M, Liljegren A, Ilencikova D, Abele A, Kyriacou K, Van Asperen C, Kiemeney L; The IMPACT Study Collaborators, Easton DF, Eeles RA. British Journal of Urology International. Volume 107(1), p. 28-39. January, 2011.
Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis.
Edwards SM, Evans DG, Hope Q, Norman AR, Barbachano Y, Bullock S, Kote-Jarai Z, Meitz J, Falconer A, Osin P, Fisher C, Guy M, Jhavar SG, Hall AL, O'Brien LT, Gehr-Swain BN, Wilkinson RA, Forrest MS, Dearnaley DP, Ardern-Jones AT, Page EC, Easton DF, Eeles RA; UK Genetic Prostate Cancer Study Collaborators and BAUS Section of Oncology. Br J Cancer 2010 Sep 27;103(6):p. 918-24. September, 2010.
Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype
Mitra, A, Fisher, C, et. al. British Journal of Cancer, Volume 98(2), p. 502-507. January, 2008.
Prostate Cancer Progression and Survival in BRCA2 Mutation Carriers
Tryggvadóttir L, Vidarsdóttir L, Thorgeirsson T, Jonasson JG, Olafsdóttir EJ, Olafsdóttir GH, Rafnar T, Thorlacius S, Jonsson E, Eyfjord JE, Tulinius H. Journal of the National Cancer Institute. Volume 99(12), p. 929-935. June, 2007.
BRCA Mutations and Risk of Prostate Cancer in Ashkenazi Jews
Tomas Kirchhoff, Noah D. Kauff, Nandita Mitra, Kedoudja Nafa, Helen Huang, Crystal Palmer, Tony Gulati, Eve Wadsworth, Sheri Donat, Mark E. Robson, Nathan A. Ellis and Kenneth Offit. Clinical Cancer Research. Volume 10, p. 2918-2921, May 1, 2004.
Two percent of men with early onset prostate cancer harbor germline mutations in the BRCA2 gene.
Edwards SM, Kote-Jarai Z, Meitz J, Hamoudi R, Hope Q, Osin P, Jackson R, Southgate C, Singh R, Falconer A, Dearnaley DP, Ardern-Jones A, Murkin A, Dowe A, Kelly J, Williams S, Oram R, Stevens M, Teare DM, Ponder BA, Gayther SA, Easton DF, Eeles RA; Cancer Research UK/Bristish Prostate Group UK Familial Prostate Cancer Study Collaborators; British Association of Urological Surgeons Section of Oncology. Am J Hum Genet. 72(1):p. 1-12. January, 2003.
Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype.
Mitra A, Fisher C, Foster CS, Jameson C, Barbachanno Y, Bartlett J, Bancroft E, Doherty R, Kote-Jarai Z, Peock S, Easton D; IMPACT and EMBRACE Collaborators, Eeles R. Br J Cancer, 22; 99(2): p. 502-507. July, 2008.
Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.
This site has been made possible by a generous grant from Morphotek.